CYTOSORBENTS MEDICAL INC — Department of Defense SBIR Phase II: CBD152-003
CYTOSORBENTS MEDICAL INC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $999,997 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code CBD152-003 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $999,997
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase II
- Topic
- CBD152-003
- Solicitation
- 2015.2
- NAICS
- —
- Place of performance
- NJ
- Period
- 2017-02-01 → 2019-01-31
Description
Certain species of fungi produce mycotoxins, which can cause acute toxicity and even death in human that either have been, or potentiallycould be, used by bioterroists as weapons of mass destruction. Aflatoxin and trichothecene T-2 toxin are two mycotoxins that are of particularconcern as potential biological weapons due to their toxicity, environmental stability, easy accessibility, historical production for use inbiowarfare and lack of specific therapy. We propose applying our broad spectrum hemoadsorbent CytoSorb as a medical countermeasure. Wehypothesize that hemoadsorption will have a significant impact on survival by directly reducing the toxin level as well as reducing the levels ofdamage-associated molecules released into circulation. During the Phase I, we demonstrated the ability of CytoSorb to efficiently remove>99% of the aflatoxin and T-2 toxin from whole blood in vitro. For Phase II we propose in vivo studies to demonstrate the efficacy our polymerin reducing systemic toxicity caused by mycotoxins. Further we proposed advancing the development of our hemoadsorption device to meetmilitary supply logistics. The outcome will be the demonstration of a safe and effective method for removal of aflatoxin and T-2 toxin fromblood, a currently unaddressed area of relevance for biowarfare defense.